OGN Organon & Co.

52주 신고가.

종가$13.75
시가총액$36억
업종헬스케어
다음 실적 발표2026-11-09
PER17.3배
매출 성장(최근 4분기)-2.5%
애널리스트 순상향률-17%
목표가 상승여력-18%
공매도 거래 비중56%
1년 수익률+50%

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle sti

2026-10-21 기준 · 출처: SEC EDGAR, FINRA, yfinance · 정보 제공용이며 투자 권유가 아닙니다

같은 업종 종목